As per the report published by Allied market Research, The Diabetic Nephropathy Market was valued at $1.9 billion in 2021, and is projected to reach $3.3 billion by 2031, growing at a CAGR of 6% from 2022 to 2031. Diabetic nephropathy is a chronic kidney disease that can affect people with diabetes. This happens when the kidneys fail due to high blood glucose levels. It can occur in people with type-2 diabetes. Diabetic nephropathy is caused by damage to the smallest blood vessels. Both kidneys begin to release protein into the urine when the small blood vessels begin to damage.
Up to 40% of people with type-1 diabetes eventually develop significant kidney disease, sometimes requiring dialysis or a kidney transplant. Only 4 to 6% of all patients with type-2 diabetes require dialysis, although about 20-30% of people with type-2 diabetes develop some kidney damage. About 40% of all people who need to start dialysis have kidney failure from type-1 or type-2 diabetes.
๐๐๐ญ ๐๐ฉ ๐๐จ ๐๐% ๐๐ข๐ฌ๐๐จ๐ฎ๐ง๐ญ, ๐๐ข๐ฅ๐ฅ ๐ญ๐ก๐ ๐๐๐ญ๐ ๐๐๐ญ๐ก ๐จ๐ ๐๐ฎ๐ ๐ฎ๐ฌ๐ญ ๐๐๐๐.
Explore More Insights@ https://www.alliedmarketresearch.com/request-sample/16978
The market has grown due to increasing prevalence of various kidney diseases and increase in tests, which is expected to provide lucrative opportunities for market expansion. The major factors driving the diabetic nephropathy market are the increase in the geriatric population suffering from diabetic nephropathy, the continuous increase in the range of conditions that can be treated with diabetic nephropathy drugs, and the growing demand for anti-diabetic drugs.
Diabetic nephropathy can be controlled with medication, a low-protein diet, a healthy lifestyle, exercise, and proper screening to prevent kidney failure. Furthermore, diabetic nephropathy medicine works by controlling blood glucose levels, lowering cholesterol levels, and lowering high blood pressure (hypertension).
Moreover, increase in initiatives by government and non-government organizations to raise awareness about diabetic nephropathy contributes significantly to the growth of the industry. Widespread use of diabetic nephropathy medication and increased diagnostic tests for diabetic nephropathy have increased the diabetic nephropathy market share
Purchase Inquiry @ https://www.alliedmarketresearch.com/purchase-enquiry/16978
According to FDA data published in 2019, about 40% of pharmaceutical manufacturing units were set up in India and China for active pharmaceutical ingredients. This has seriously affected the supply chain of medicines. The healthcare industry in developing nations is projected to grow significantly due to various factors including increasing investment in both public and private sectors, increase in chronic diseases, increasing number of diabetic patients and population growth.
On the basis of drug class, the market is classified into angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, calcium channel blockers, diuretics, renin inhibitors, and others. By type, the market is segmented into type-1 diabetes and type-2 diabetes. Depending on the distribution channel, it is segmented into hospital pharmacies, online providers and drug and retail pharmacies. Based on drug class, diabetic nephropathy market size, the angiotensin-converting enzyme inhibitor segment was the largest revenue contributor to the global market in 2021, along with temporary and permanent chronic heart disease, heart attack, hypertension, and diabetic nephropathy. The diuretics segment is expected to witness highest CAGR of 7.4% during the forecast period owing to rise in awareness and surge in cases of oedema, hypertension, kidney stones and diabetic nephropathy.
Customization Request@ https://www.alliedmarketresearch.com/request-for-customization/16978
North America generated maximum revenue in 2021, due to increase in number of patient admissions and chronic kidney diseases. Asia-Pacific is expected to witness the highest CAGR during the forecast period due to increase in diabetic nephropathy cases, chronic heart disease cases and hypertension.
Key Benefits:
โข A quantitative analysis of the market segments, current trends, estimations, and dynamics of the diabetic nephropathy market analysis from 2021 to 2031 to identify the prevailing diabetic nephropathy market opportunity.
โข The market research is offered along with information related to key drivers, restraints, and opportunities.
โข Porter’s five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
โข In-depth analysis of the diabetic nephropathy market segmentation assists to determine the prevailing market opportunities.
โข Major countries in each region are mapped according to their revenue contribution to the global market.
Key Market Players
โข AbbVie Inc.
โข Abbott Laboratories
โข Bayer AG
โข Eli Lilly and Company
โข Merck & Co
โข Astrazenica Plc
โข Novartis AG
โข Pfizer Inc.
โข Reata Pharmaceuticals
โข Sanofi
Related Report:
Dental Burs and Endodontic Market
Non-surgical Aesthetic Market
About Us:
Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP, based in Portland, Oregon. AMR provides global enterprises as well as medium and small businesses with unmatched quality of โMarket Research Reportsโ and โBusiness Intelligence Solutions.โ AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.
AMR introduces its online premium subscription-based library Avenue, designed specifically to offer cost-effective, one-stop solution for enterprises, investors, and universities. With Avenue, subscribers can avail an entire repository of reports on more than 2,000 niche industries and more than 12,000 company profiles. Moreover, users can get an online access to quantitative and qualitative data in PDF and Excel formats along with analyst support, customization, and updated versions of reports.
๐๐จ๐ง๐ญ๐๐๐ญ:
David Correa
5933 NE Win Sivers Drive
205, Portland, OR 97220
United States
Toll Free: 1-800-792-5285
UK: +44-845-528-1300
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
Fax: +1-855-550-5975
help@alliedmarketresearch.com
Web: https://www.alliedmarketresearch.com